Syngene International reports 36% profit fall as revenue edges up 2.6%
Verified article - details checked for accuracy.
Data Extracted via Frism DocuLens
Syngene International Limited posted modest revenue growth but a sharp 36% profit plunge, prompting a modest dividend and highlighting tighter cash liquidity amid strategic capacity upgrades.
- Revenue rose 2.6% to Rs 37,387 mn, while net profit fell ‑36% to Rs 3,167 mn and diluted EPS dropped ‑36% to Rs 7.87.
- Cash & cash equivalents slumped ‑38% to Rs 2,286 mn, and operating cash flow fell 22% YoY to Rs 9,152 mn, tightening liquidity.
- Board recommended a final dividend of Rs 1.25 per share (record date 26 Jun 2026).
- New US biologics site adds 50,000 L single‑use bioreactor capacity; Bangalore licence and bonded warehouse boost commercial‑scale biologics capability.
- Profit pressure stems from higher employee‑benefit costs (+10% YoY), FX losses (~Rs 210 mn), and increased depreciation on newly capitalised assets.
Complete ArticleExclusive Frism Intelligence Report
Frism is a financial information and news discovery platform. We provide factual summaries and data correlations for educational and informational purposes only. Frism does not provide investment advice, buy/sell recommendations, or directional market outlooks. Users should consult a qualified financial advisor before making any investment decisions.
Proudly crafted in India 🇮🇳
Frism Computing (OPC) Private Limited
#74, 15TH CROSS, JP Nagar III Phase, Bangalore South, Bangalore 560078, Karnataka